Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.
The last earnings update was 23 days ago.
More info.

The calculations below outline how an intrinsic value for
Integra LifeSciences Holdings
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Current Discount

Amount off the current price
Integra LifeSciences Holdings
is available for.

14%

Share price is
€49.03
vs Future cash flow value of
€57.14

Current Discount Checks

For
Integra LifeSciences Holdings
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.

Integra LifeSciences Holdings's share price is below the future cash flow value, but not at a moderate discount (< 20%).

Integra LifeSciences Holdings's share price is below the future cash flow value, but not at a substantial discount (< 40%).

PRICE RELATIVE TO MARKET

We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for
Integra LifeSciences Holdings's
earnings,
growth
and
assets
is considered below, and whether this is a fair price.

Price based on past earnings

Are
Integra LifeSciences Holdings's earnings available for a low price, and how does
this compare to other companies in the same industry?

High Growth Checks

Integra LifeSciences Holdings's earnings are expected to grow significantly at over 20% yearly.

Integra LifeSciences Holdings's revenue is expected to grow by 4.6% yearly, however this is not considered high growth (20% yearly).

Past and Future Earnings per Share

The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.

Past performance checks

We assess
Integra LifeSciences Holdings's performance over the past 5 years by checking for:

Has earnings increased in past 5 years? (1 check)

Has the earnings growth in the last year exceeded that of the
Medical Equipment
industry? (1 check)

Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)

Is the Return on Equity (ROE) higher than 20%? (1 check)

Is the Return on Assets (ROA) above industry average? (1 check)

Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)

The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Integra LifeSciences Holdings
has a total score of
1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Health

A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).

The boxes below represent the relative size of what makes up
Integra LifeSciences Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.

Net Worth

Integra LifeSciences Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Integra LifeSciences Holdings's long term commitments exceed its cash and other short term assets.

Balance sheet

This treemap shows a more detailed breakdown of
Integra LifeSciences Holdings's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
checks below.

Assets

Liabilities and shares

The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.6x debt.

Historical Debt

Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.

Management

Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.

CEO

PeteArduini

COMPENSATION

$7,134,568

AGE

53

TENURE AS CEO

7.2 years

CEO Bio

Mr. Peter J. Arduini, also known as Pete, has been Chief Executive Officer and President at Derma Sciences, Inc. since February 2017. Mr. Arduini has been the Chief Executive Officer of Integra LifeSciences Holdings Corporation since January 3, 2012 and has been its President since November 1, 2010. Mr. Arduini serves as the Chief Executive Officer and President of Integra Lifesciences Corporation. He served as the Chief Operating Officer of Integra LifeSciences Holdings Corporation from November 1, 2010 to January 3, 2012. Before joining Integra, he served as Corporate Vice President and President of Medication Delivery Business at Baxter Healthcare Corporation from 2005 to 2010. He served as the President of Medication Delivery Business of Baxter International Inc. and Baxter World Trade Corporation (subsidiaries of Baxter International, Inc.) from April 2005 to October 29, 2010. He served as Corporate Vice President at Baxter International Inc. from April 2005 to October 2010. Prior to joining Baxter, he served on General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business. Along with having served in sales management, He also has overseen marketing, market research, product design and engineering program development for its radiology & cardiology franchise. He served as the Global General Manager of General Electric Healthcares’ Cat Scan (CT) and functional imaging business. He also served as General Manager of USA Sales, for GE’s diagnostic imaging business. Prior to joining GE, He spent four years with Procter and Gamble. He serves as a Director of Bristol-Myers Squibb Farmacêutica Portuguesa, SA. He has been a Director of Derma Sciences, Inc. since February 2017. He has been a Director of Integra LifeSciences Holdings Corporation since January 2012. He has been an Independent Director of Bristol-Myers Squibb Company since April 01, 2016. Mr. Arduini also serves on the Board of Directors of ADVAMED (the Advanced Medical Technology Association), the Board of Directors of MDIC (the Medical Device Innovation Consortium), and the Board of Directors of the National Italian American Foundation. He also serves on the Board of Trustees of Susquehanna University. He served as a Director of SeaSpine Holdings Corporation until July 01, 2015. Mr. Arduini received his Master’s in Business Administration Degree from Northwestern University’s Kellogg Graduate School of Management, after graduating from Susquehanna University with a Bachelor of Science degree in Marketing.

CEO Compensation

Pete's compensation has been consistent with company performance over the past year.

Pete's remuneration is higher than average for companies of similar size in Germany.

Management Team Tenure

Average tenure and age of the
Integra LifeSciences Holdings
management team in years:

6.3

Average Tenure

57

Average Age

The average tenure for the Integra LifeSciences Holdings management team is over 5 years, this suggests they are a seasoned and experienced team.

Management Team

Pete Arduini

TITLE

President

COMPENSATION

$7M

AGE

53

TENURE

7.2 yrs

Richard Caruso

TITLE

Founder and Chairman Emeritus

COMPENSATION

$38K

AGE

75

TENURE

30.2 yrs

Glenn Coleman

TITLE

Corporate VP of International & CFO

COMPENSATION

$2M

AGE

50

TENURE

4.8 yrs

Dan Reuvers

TITLE

Corporate VP and President of Specialty Surgical Solutions

COMPENSATION

$1M

AGE

55

TENURE

6.3 yrs

Bob Davis

TITLE

Corporate VP and President of Orthopedics & Tissue Technologies

COMPENSATION

$1M

AGE

59

TENURE

6.3 yrs

John Mooradian

TITLE

Corporate Vice President of Global Operations & Supply Chain

COMPENSATION

$756K

AGE

62

TENURE

6.3 yrs

Jeffrey Mosebrook

TITLE

VP, Principal Accounting Officer

AGE

42

TENURE

1.4 yrs

Ken Burhop

TITLE

Corporate VP & Chief Scientific Officer

AGE

64

TENURE

5.1 yrs

William Compton

TITLE

Chief Information Officer & Senior VP

Sravan Emany

TITLE

Senior Vice President of Strategy

TENURE

1.1 yrs

Board of Directors Tenure

Average tenure and age of the
Integra LifeSciences Holdings
board of directors in years:

6.6

Average Tenure

60.5

Average Age

The tenure for the Integra LifeSciences Holdings board of directors is about average.

Board of Directors

Stuart Essig

TITLE

Chairman

COMPENSATION

$370K

AGE

56

TENURE

7.2 yrs

Pete Arduini

TITLE

President

COMPENSATION

$7M

AGE

53

TENURE

7.2 yrs

Richard Caruso

TITLE

Founder and Chairman Emeritus

COMPENSATION

$38K

AGE

75

TENURE

1.8 yrs

Chris Schade

TITLE

Director

COMPENSATION

$260K

AGE

57

TENURE

13.2 yrs

Ray Murphy

TITLE

Director

COMPENSATION

$260K

AGE

70

TENURE

9.9 yrs

Barbara Hill

TITLE

Presiding Director

COMPENSATION

$245K

AGE

66

TENURE

0.5 yrs

Donald Morel

TITLE

Director

COMPENSATION

$245K

AGE

60

TENURE

5.6 yrs

Keith N. Bradley

TITLE

Director

COMPENSATION

$260K

AGE

73

TENURE

27.2 yrs

Lloyd Howell

TITLE

Director

COMPENSATION

$245K

AGE

51

TENURE

6 yrs

Rhonda Ballintyn

TITLE

Director

AGE

61

TENURE

0.2 yrs

Who owns this company?

Recent Insider Trading

More shares have been bought than sold by Integra LifeSciences Holdings insiders in the past 3 months.

News

Simply Wall St News

Company Info

Description

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, Asia Pacific, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.